28 July 2024 - Luye Pharma today announced that the US FDA has approved the company's Erzofri (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilisers or anti-depressants.

Erzofri, administered once a month, is the first patented paliperidone palmitate long-acting injection developed in China to get approved in the US.

Read Luye Pharma press release